Patents by Inventor Avigdor Levanon

Avigdor Levanon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5824641
    Abstract: A novel polypeptide derived from the leech Hirudo medicinalis was found to be able to inhibit Factor Xa thereby reducing the extent of blood coagulation. The polypeptide is useful in treating conditions of excessive blood coagulation. A recombinant organism containing cDNA encoding the polypeptide has been deposited in the ATCC under Accession No. 69134. Recombinant microorganisms able to produce the polypeptide have been deposited in the ATCC under Accession Nos. 69135, 69137 and 69269.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 20, 1998
    Assignee: Bio-Technology General Corp
    Inventors: Elisha P. Zeelon, Moshe M. Werber, Avigdor Levanon
  • Patent number: 5801017
    Abstract: The present invention provides a recombinant polypeptide having the amino acid sequence X-tyr.sup.26 -gly.sup.110 where tyr.sup.26 -gly.sup.110 is identical to the sequence shown in FIG. 10, and wherein X is methionine or absent and wherein asn.sup.72 may be substituted by pro.The invention further provides a method of producing the polypeptide which comprises transforming a host cell with an expression plasmid encoding the polypeptide, culturing the transformed host cell so that the cell produces the polypeptide encoded by the plasmid, and a method of recovering the polypeptide so produced.
    Type: Grant
    Filed: April 8, 1994
    Date of Patent: September 1, 1998
    Assignee: Bio-Technology General Corp.
    Inventors: Moshe M. Werber, Elisha P. Zeelon, Avigdor Levanon, Rachel Guy, Arie Goldlust, Meir Rigbi, Amos Panet, Meir Fischer
  • Patent number: 5783421
    Abstract: A novel polypeptide derived from the leech Hirudo medicinalis was found to be able to inhibit Factor Xa thereby reducing the extent of blood coagulation. The polypeptide is useful in treating conditions of excessive blood coagulation. A recombinant organism containing cDNA encoding the polypeptide has been deposited in the ATCC under Accession No. 69134. Recombinant microorganisms able to produce the polypeptide have been deposited in the ATCC under Accession Nos. 69135, 69137 and 69269.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 21, 1998
    Assignee: Bio-Technology General Corp.
    Inventors: Elisha P. Zeelon, Moshe M. Werber, Avigdor Levanon
  • Patent number: 5759816
    Abstract: An improved vector upon introduction into a suitable host containing the thermolabile repressor C.sub.I renders the host capable of effecting expression of a desired gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: the promoter and operator P.sub.L O.sub.L from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal binding site; an ATG initiation codon or DNA which is converted into an ATG initiation codon upon insertion of the desired gene into the vector; a second restriction enzyme site for inserting the gene in phase with the ATG codon; a T.sub.1 T.sub.2 rRNA transcription termination sequence; an origin of replication and a gene associated with a selectable or identifiable phenotypic trait manifested when the vector is present in the host. The distance between the 3' end of the P.sub.L O.sub.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: June 2, 1998
    Assignee: Bio-Technology General Corp.
    Inventors: Amos B. Oppenheim, Avigdor Levanon, Hilla Locker-Giladi, Marian Gorecki, Tikva Vogel
  • Patent number: 5679320
    Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imagifig a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.
    Type: Grant
    Filed: June 14, 1994
    Date of Patent: October 21, 1997
    Assignee: Bio-Technology General Corp.
    Inventors: Tikva Vogel, Avigdor Levanon, Moshe M. Werber, Rachel Guy, Amos Panet, Jacob Hartman, Hadassa Shaked
  • Patent number: 5670371
    Abstract: A plasmid for the production of superoxide dismutase or an analog thereof which upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of DNA encoding superoxide dismutase and production of superoxide dismutase. The plasmid is a double-stranded DNA molecule which includes in 5' to 3' order the following: a DNA sequence which contains the promoter and operator P.sub.L O.sub.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: September 23, 1997
    Assignee: Bio-Technology General Corp.
    Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Jacob Hartman
  • Patent number: 5637495
    Abstract: An improved vector upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of a desired gene inserted into the vector and production of polypeptide encoded by the gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: a DNA sequence which contains the promoter and operator P.sub.L O.sub.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: June 10, 1997
    Assignee: Bio-Technology General Corp.
    Inventors: Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel
  • Patent number: 5527691
    Abstract: An improved vector upon introduction into a suitable host containing the thermolabile repressor C.sub.I renders the host capable of effecting expression of a desired gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: the promoter and operator P.sub.L O.sub.L from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal binding site; an ATG initiation codon or DNA which is converted into an ATG initiation codon upon insertion of the desired gene into the vector; a second restriction enzyme site for inserting the gene in phase with the ATG codon; a T.sub.1 T.sub.2 rRNA transcription termination sequence; an origin of replication and a gene associated with a selectable or identifiable phenotypic trait manifested when the vector is present in the host. The distance between the 3' end of the P.sub.L O.sub.
    Type: Grant
    Filed: June 28, 1994
    Date of Patent: June 18, 1996
    Assignee: Bio-Technology General Corp.
    Inventors: Amos B. Oppenheim, Avigdor Levanon, Hilla Locker-Galadi, Marian Gorecki, Tikva Vogil
  • Patent number: 5455158
    Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.
    Type: Grant
    Filed: May 4, 1993
    Date of Patent: October 3, 1995
    Assignee: Bio-Technology General Corp.
    Inventors: Tikva Vogel, Avigdor Levanon, Moshe M. Werber, Rachel Guy, Amos Panet
  • Patent number: 5270030
    Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.
    Type: Grant
    Filed: May 21, 1990
    Date of Patent: December 14, 1993
    Assignee: Bio-Technology General Corp.
    Inventors: Tikva Vogel, Avigdor Levanon, Moshe M. Werber, Rachel Guy, Amos Panet
  • Patent number: 5256546
    Abstract: A plasmid for the production of porcine growth hormone or an analog thereof which upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of DNA encoding porcine growth hormone and production of porcine growth hormone or analogs thereof.
    Type: Grant
    Filed: February 24, 1992
    Date of Patent: October 26, 1993
    Assignee: Bio-Technology General Corp.
    Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Elisha Zeelon, Menachem Zeevi
  • Patent number: 5198361
    Abstract: An improved vector upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of a desired gene inserted into the vector and production of polypeptide encoded by the gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: a DNA sequence which contains the promoter and operator P.sub.L O.sub.
    Type: Grant
    Filed: January 3, 1991
    Date of Patent: March 30, 1993
    Assignee: Bio-Technology General Corp.
    Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Elisha Zeelon, Menachem Zeevi
  • Patent number: 5151364
    Abstract: An improved vector upon introduction into a suitable host containing the thermolabile repressor C.sub.I renders the host capable of effecting expression of a desired gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: the promoter and operator P.sub.L O.sub.L from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal binding site for transcribing mRNA; and ATG initiation codon or DNA which is converted into an ATG initiation codon upon insertion of the desired gene into the vector; a second restriction enzyme site for inserting the gene in phase with the ATG codon; a T.sub.1 T.sub.
    Type: Grant
    Filed: January 14, 1992
    Date of Patent: September 29, 1992
    Assignee: Bio-Technology General Corp.
    Inventors: Avigdor Levanon, Amos B. Oppenheim, Hilla Locker-Giladi
  • Patent number: 5126252
    Abstract: An improved vector upon introduction into a suitable host containing the thermolabile repressor C.sub.I renders the host capable of effecting expression of a desired gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: the promoter and operator P.sub.L O.sub.L from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal binding site; an ATG initiation codon or DNA which is converted into an ATG initiation codon upon insertion of the desired gene into the vector; a second restriction enzyme site for inserting the gene in phase with the ATG codon; a T.sub.1 T.sub.2 rRNA transcription termination sequence; an origin of replication and a gene associated with a selectable or identificable phenotypic trait manifested when the vector is present in the host. The distance between the 3' end of the P.sub.L O.sub.
    Type: Grant
    Filed: March 1, 1989
    Date of Patent: June 30, 1992
    Assignee: Bio-Technology General Corp.
    Inventors: Amos B. Oppenheim, Avigdor Levanon, Hilla Locker-Galadi, Marian Gorecki
  • Patent number: 5112744
    Abstract: An improved vector upon introduction into a suitable host containing the thermolabile repressor C.sub.I renders the host capable of effecting expression of a desired gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: the promoter and operator P.sub.L O.sub.L from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal binding site; and ATG initiation codon or DNA which is converted into and ATG initiation codon upon insertion of the desired gene into the vector; a second restriction enzyme site for inserting the gene in phase with the ATG codon; a T.sub.1 T.sub.2 rRNA transcription termination sequence; and origin of replication and a gene associated with a selectable or identifiable phenotypic trait manifested when the vector is present in the host. The distance between the 3' end of the P.sub.L O.sub.
    Type: Grant
    Filed: June 15, 1990
    Date of Patent: May 12, 1992
    Assignee: Bio-Technology General Corp.
    Inventors: Amos B. Oppenheim, Avigdor Levanon, Hilla Locker-Galadi, Marian Gorecki
  • Patent number: 5081020
    Abstract: An improved vector upon introduction into a suitable host containing the thermolabile repressor C.sub.I renders the host capable of effecting expression of a desired gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: the promoter and operator P.sub.L O.sub.L from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal binding site for transcribing mRNA; an ATG initiation codon or DNA which is converted into an ATG initiation codon upon insertion of the desired gene into the vector; a second restriction enzyme site for inserting the gene in phase with the ATG codon; a T.sub.1 T.sub.
    Type: Grant
    Filed: July 18, 1988
    Date of Patent: January 14, 1992
    Assignee: Bio-Technology General Corp.
    Inventors: Avigdor Levanon, Amos B. Oppenheim, Hilla Locker-Giladi
  • Patent number: 4997916
    Abstract: A method is provided for recovering a purified animal growth hormone or a polypeptide analog thereof having substantially the same amino acid sequence as, and the biological activity of, the corresponding naturally-occurring animal growth hormone from a bacterial cell in which the animal growth hormone or polypeptide analog has been produced by means of expression of a plasmid encoding the hormone or polypeptide analog which comprises: (a) disrupting the cell wall of the bacterial cell in a buffered neutral pH solution so as to produce a lysate containing precipitated hormone or polypeptide analog; (b) recovering the resulting precipitated hormone or polypeptide analog; (c) suspending the precipitated hormone or polypeptide analog so recovered in distilled water; (d) treating the resulting precipitate-containing suspension with a sodium hydroxide solution having an alkaline pH of about 11.
    Type: Grant
    Filed: March 7, 1989
    Date of Patent: March 5, 1991
    Assignee: Bio-Technology General Corp.
    Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Elisha Zeelon, Menachem Zeevi
  • Patent number: 4871835
    Abstract: Analogs of hGH having the activity of naturally occurring hGH and a similar amino acid sequence varying from the sequence of natural hGh by the addition of one or more amino acids, e.g. methione or methionine-leucine, to the N-terminus of natural hGH have been produced, recovered and purified. Such analogs may be incorporated into pharmaceutical compositions and administered to a subject to increase the level of hGH in the subject.Analogs of hGH which comprise the amino acid sequence of natural hGH from the N-terminus of which one or more amino acids have been deleted, e.g. Met.sup.14 hGh, have been produced, recovered and purified. Such analogs may be incorporated into pharmaceutical compositions and administered to a subject to lower the level of hGH in the subject.A plasmid has been constructed which directs the expression of an analog of hGH having the amino acid sequence methionine-leucine added to the N-terminus of natural hGH.
    Type: Grant
    Filed: January 14, 1985
    Date of Patent: October 3, 1989
    Assignee: Bio-Technology General Corp.
    Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Pinhas E. Zeelon, Menachem Zeevi
  • Patent number: 4831120
    Abstract: An improved vector upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of a desired gene inserted into the vector and production of polypeptide encoded by the gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: a DNA sequence which contains the promoter and operator P.sub.L O.sub.
    Type: Grant
    Filed: July 3, 1985
    Date of Patent: May 16, 1989
    Assignee: Bio-Technology General Corp.
    Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Elisha Zeelon, Menachem Zeevi